SIGA Technologies Inc. (SIGA)

[mick]

$SIGA SIGA Technologies, Inc., a bio-defense company, engages in the discovery, development,

and commercialization of products for use in defense against biological warfare agents comprising smallpox and arenaviruses.

It also involves in the discovery and development of other novel anti-infectives and antibiotics for the prevention and treatment of serious infectious diseases.

The company primarily offers ST-246, an orally administered antiviral drug that targets orthopox viruses.

It also develops anti-arenavirus drug candidates, such as ST-294 and ST-193, which demonstrate antiviral activity in cell culture assays against arenavirus pathogens;

and broad spectrum antiviral candidate, ST-669, against viruses in the Poxviridae,
Filoviridae,
Bunyaviridae,
Arenaviridae,
Flaviviridae,
Togaviridae,
Retroviridae, and
Picornaviridae families.

In addition, the company has four drug series in the pre-clinical development stage,
including ST-610 and ST-148 for dengue virus of the genus Flavivirus.

SIGA Technologies, Inc. was founded in 1995 and is headquartered in New York, New York